Large-cap Health Care company ResMed has moved -0.5% so far today on a volume of 69,973, compared to its average of 1,666,859. In contrast, the S&P 500 index moved -1.0%.
ResMed trades -23.05% away from its average analyst target price of $184.0 per share. The 8 analysts following the stock have set target prices ranging from $165.0 to $220.0, and on average have given ResMed a rating of buy.
If you are considering an investment in RMD, you'll want to know the following:
-
ResMed's current price is 128.0% above its Graham number of $62.1, which implies that at its current valuation it does not offer a margin of safety
-
ResMed has moved -39.0% over the last year, and the S&P 500 logged a change of 11.0%
-
Based on its trailing earnings per share of 6.09, ResMed has a trailing 12 month Price to Earnings (P/E) ratio of 23.2 while the S&P 500 average is 15.97
-
RMD has a forward P/E ratio of 18.3 based on its forward 12 month price to earnings (EPS) of $7.75 per share
-
The company has a price to earnings growth (PEG) ratio of 1.78 — a number near or below 1 signifying that ResMed is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 5.04 compared to its sector average of 4.16
-
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.
-
Based in San Diego, the company has 10,140 full time employees and a market cap of $20.83 Billion. ResMed currently returns an annual dividend yield of 1.2%.